prikaz prve stranice dokumenta Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies
  Preuzmi
PDF 603.1 KB
Znanstveni rad - Izvorni znanstveni rad
Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies
Radiology and Oncology, 58 (2024), 2; 258-267. https://doi.org/10.2478/raon-2024-0030
Borstnar, Simona; Bozovic-Spasojevic, Ivana; Cvetanovic, Ana; Dedić Plavetić, Natalija; Konsoulova, Assia; Matos, Erika; Popovic, Lazar; Popovska, Savelina; Tomić, Snježana; Vrdoljak, Eduard

Citirajte ovaj rad

Borstnar, S., Bozovic Spasojevic, I., Cvetanovic, A., Dedić Plavetić, N., Konsoulova, A., Matos, E. ... Vrdoljak, E. (2024). Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies. Radiology and Oncology, 58. (2), 258-267. doi: 10.2478/raon-2024-0030

Borstnar, Simona, et al. "Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies." Radiology and Oncology, vol. 58, br. 2, 2024, str. 258-267. https://doi.org/10.2478/raon-2024-0030

Borstnar, Simona, Ivana Bozovic Spasojevic, Ana Cvetanovic, Natalija Dedić Plavetić, Assia Konsoulova, Erika Matos, Lazar Popovic, Savelina Popovska, Snježana Tomić i Eduard Vrdoljak. "Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies." Radiology and Oncology 58, br. 2 (2024): 258-267. https://doi.org/10.2478/raon-2024-0030

Borstnar, S., et al. (2024) 'Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies', Radiology and Oncology, 58(2), str. 258-267. doi: 10.2478/raon-2024-0030

Borstnar S, Bozovic Spasojevic I, Cvetanovic A, Dedić Plavetić N, Konsoulova A, Matos E, i sur.. Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies. Radiology and Oncology [Internet]. 11.06.2024. [pristupljeno 30.01.2025.];58(2):258-267. doi: 10.2478/raon-2024-0030

S. Borstnar, et al., "Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies", Radiology and Oncology, vol. 58, br. 2, str. 258-267, Lipanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:699972. [Citirano: 30.01.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:699972
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies
AutorSimona Borstnar
AutorIvana Bozovic-Spasojevic
AutorAna Cvetanovic
AutorNatalija Dedić Plavetić
AutorAssia Konsoulova
AutorErika Matos
AutorLazar Popovic
AutorSavelina Popovska
AutorSnježana Tomić
AutorEduard Vrdoljak
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PATOFIZIOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Patofiziologija
Sažetak (engleski)
Background: Recent evidence brought by novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates is leading to significant changes in HER2-negative breast cancer (BC) best practices. A new targetable category termed 'HER2-low' has been identified in tumors previously classified as 'HER2-negative'. Daily practice in pathology and medical oncology is expected to align to current recommendations, but patient access to novel anticancer drugs across geographies might be impeded due to local challenges. Materials and methods: An expert meeting involving ten regional pathology and oncology opinion leaders experienced in BC management in four Central and Eastern Europe (CEE) countries (Bulgaria, Croatia, Serbia, Slovenia) was held. Herein we summarized the current situation of HER2-low metastatic BC (mBC), local challenges, and action plans to prevent delays in patient access to testing and treatment based on expert opinion. Results: Gaps and differences at multiple levels were identified across the four countries. These included variability in the local HER2-low epidemiology data, certification of pathology laboratories and quality control, and reimbursement conditions of testing and anticancer drugs for HER2-negative mBC. While clinical decisions were aligned to international guidelines in use, optimal access to testing and innovative treatment was restricted due to significant delays in reimbursement or limitative reimbursement conditions. Conclusions: Preventing delays in HER2-low mBC patient access to diagnosis and novel treatments is crucial to optimize outcomes. Multidisciplinary joint efforts and pro-active discussions between clinicians and decision makers are needed to improve care of HER2-low mBC patients in CEE countries.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaRadiology and Oncology
Brojčani podacivol. 58, br. 2, str. 258-267
e-ISSN1581-3207
DOIhttps://doi.org/10.2478/raon-2024-0030
URN:NBNurn:nbn:hr:105:699972
Datum objave publikacije2024-06-11
URL dokumentahttps://www.sciendo.com/article/10.2478/raon-2024-0030
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2025-01-27 09:31:17